Expanded Access Program for Lorcaserin (Belviq)

Go Back to All Clinical Trials

Expanded Access Program for Lorcaserin (Belviq)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Age: Between 0 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Participants with confirmed diagnosis of Dravet syndrome
2. Participants currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304
3. Participants who have a clinical benefit from lorcaserin in the opinion of the treating physician

You may not be eligible for this study if the following are true:

1. Those who do not meet the inclusion criteria

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies